Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TuHURA Biosciences, Inc./NVHURA · Entity 6601 | Chief Financial Officer | January 06, 2026 | January 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TuHURA Biosciences, Inc./NV
Report date January 06, 2026 · Filed January 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.73 · Expires 2036-01-06 | Direct | 273,696 |
Reported balance
After 2026-01-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-06 · Grant · Acquired 273,696 · Balance 273,696 F1: Represents a supplemental option grant to the option grant previously made in December 2025. One-third of the stock options become exercisable on the first, second, and third anniversary of January 6, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a supplemental option grant to the option grant previously made in December 2025. One-third of the stock options become exercisable on the first, second, and third anniversary of January 6, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 06, 2026 Filed Jan 8, 2026 21:35 UTC | TuHURA Biosciences, Inc./NV HURA · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 273,696 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0000897069-26-000112 · form4.xml · derivative · entry 1 Dearborn Dan · CIK 0001975443 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 273,696 Underlying: Common Stock · 273,696 shares Expires 2036-01-06 F1 · derivative.exercise_date: Represents a supplemental option grant to the option grant previously made in December 2025. One-third of the stock options become exercisable on the first, second, and third anniversary of January 6, 2025. Read SEC document |
| December 12, 2025 Filed Dec 17, 2025 11:37 UTC | TuHURA Biosciences, Inc./NV HURA · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 1,531,367 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0000897069-25-001809 · form4.xml · derivative · entry 1 Dearborn Dan · CIK 0001975443 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,531,367 Underlying: Common Stock · 1,531,367 shares Expires 2035-12-12 F1 · derivative.exercise_date: One-third of the stock options become exercisable on the first, second, and third anniversary of December 12, 2025. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 21:46 UTC | TuHURA Biosciences, Inc./NV HURA · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 489,848 | $0.00 Strike: $4.94 | $0.00 |
DisclosureSEC source: 0000897069-24-002164 · form4.xml · derivative · entry 1 Dearborn Dan · CIK 0001975443 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 489,848 Underlying: Common Stock · 489,848 shares Expires 2034-11-12 F1 · derivative.exercise_date: One-third of the stock options become exercisable on the first, second, and third anniversary of November 12, 2024. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 00:01 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 66,658 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0000897069-24-001992 · form4.xml · derivative · entry 5 Dearborn Dan · CIK 0001975443 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,658 Underlying: Common Stock · 66,658 shares Expires 2034-02-28 F1 · date: Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), among the Issuer (fka "Kintara Therapeutics, Inc."), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the "Merger") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to "TuHURA Biosciences, Inc." F4 · derivative.exercise_date: One-third of the stock options become exercisable on the first, second, and third anniversary of February 28, 2024. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 00:01 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 15,744 | $0.00 Strike: $3.69 | $0.00 |
DisclosureSEC source: 0000897069-24-001992 · form4.xml · derivative · entry 4 Dearborn Dan · CIK 0001975443 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,744 Underlying: Common Stock · 15,744 shares Expires 2033-04-07 F1 · date: Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), among the Issuer (fka "Kintara Therapeutics, Inc."), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the "Merger") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to "TuHURA Biosciences, Inc." F3 · derivative.exercise_date: One-third of the stock options become exercisable on the first, second, and third anniversary of April 7, 2023. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 00:01 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 232,570 | $0.00 Strike: $3.69 | $0.00 |
DisclosureSEC source: 0000897069-24-001992 · form4.xml · derivative · entry 3 Dearborn Dan · CIK 0001975443 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,570 Underlying: Common Stock · 232,570 shares Expires 2032-11-15 F1 · date: Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), among the Issuer (fka "Kintara Therapeutics, Inc."), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the "Merger") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to "TuHURA Biosciences, Inc." F2 · derivative.exercise_date: One-third of the stock options become exercisable on the first, second, and third anniversary of November 15, 2023. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 00:01 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 68,438 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0000897069-24-001992 · form4.xml · derivative · entry 2 Dearborn Dan · CIK 0001975443 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,438 Underlying: Common Stock · 68,438 shares Expires 2026-12-20 F1 · date: Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), among the Issuer (fka "Kintara Therapeutics, Inc."), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the "Merger") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to "TuHURA Biosciences, Inc." Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 00:01 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 33,991 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0000897069-24-001992 · form4.xml · derivative · entry 1 Dearborn Dan · CIK 0001975443 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,991 Underlying: Common Stock · 33,991 shares Expires 2026-01-17 F1 · date: Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), among the Issuer (fka "Kintara Therapeutics, Inc."), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the "Merger") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to "TuHURA Biosciences, Inc." Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.